Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CellaVision AB ( (SE:CEVI) ) just unveiled an update.
CellaVision AB, a Swedish-listed medtech firm, develops and sells automated microscopy and AI-based systems for blood and body fluid analysis that streamline clinical laboratory workflows and support rapid, accurate disease diagnosis. Operating through global partners and local support units in over 40 countries, it generated SEK 759 million in 2025 sales and aims for 15% annual growth over the cycle.
The company announced it will publish its first-quarter 2026 report on April 24, 2026, followed by an English-language webcast and conference call for analysts, investors and media later that morning. The scheduled presentation, led by President and CEO Simon Østergaard, offers stakeholders an opportunity to receive updates on CellaVision’s financial and operational performance, which may inform views on its progress toward growth targets and its competitive position in the medtech diagnostics market.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK158.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
More about CellaVision AB
CellaVision AB is a global medical technology company specializing in systems for routine analysis of blood and other body fluids used in healthcare diagnostics. Its automated microscopy, image analysis and AI-driven solutions replace manual lab work, improving workflow efficiency and supporting skills development across more than 40 countries through global partners and 13 local organizations.
Headquartered in Lund, Sweden, CellaVision focuses on enabling swift and accurate diagnoses, particularly for infections and serious cancers, and reported sales of SEK 759 million in 2025. The company targets average annual growth of 15% over an economic cycle and is listed on the Nasdaq Stockholm Mid Cap market, reinforcing its position as a leading provider of hematology lab automation.
Average Trading Volume: 36,595
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.57B
Learn more about CEVI stock on TipRanks’ Stock Analysis page.